Publications by authors named "Hamna Akram"
Sickle cell disease (SCD) is a group of inherited red blood cell disorders affecting millions worldwide. The median life expectancy of someone with SCD remains significantly low despite improvements in standards of care and the implementation of hydroxyurea therapy. Notably, a 20-year interval existed (after the implementation of hydroxyurea therapy) prior to the approval of other sickle cell medications, namely, l-glutamine, voxelotor, and crizanlizumab.
View Article and Find Full Text PDFPatients with non-alcoholic fatty liver disease (NAFLD) have an increased risk of developing progressive fibrosis, cirrhosis, and hepatocellular carcinoma. As of now, there are no FDA-approved treatments for NAFLD/non-alcoholic steatohepatitis (NASH) or its associated fibrosis. Although many drugs are under clinical trial, both obeticholic acid (OCA) and semaglutide are among the few that have reached phase III clinical trials, but they were never compared.
View Article and Find Full Text PDFArticle Synopsis
- Moyamoya disease is characterized by narrowing of the carotid and cerebral arteries, leading to the development of unique collateral blood vessels, and it can occur in conjunction with other disorders, especially in Down syndrome (moyamoya syndrome).
- This syndrome is frequently seen in individuals with Down syndrome, but the exact cause of this association remains unclear.
- A systematic review investigated the relationship between moyamoya syndrome and Down syndrome, identifying possible genetic factors, such as the RNF213 gene, that may contribute to vascular problems in those with trisomy 21.